Drug Vaccines

Rabavert

Payments companies reported to CMS as associated with Rabavert. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$1,117associated payments (2023-2025)

16clinicians with associated payments

1company reporting

By year

2024 $582

2025 $536

Payments reported as associated with Rabavert, per program year, as reported to CMS.

Who makes it

Bavarian Nordic A/S $1,117 associated with Rabavert (2023-2025)

Specialties most often involved

Family $470

General Practice $146

Family Medicine $120

Medical $97.38

Pediatrics $48.69

Obstetrics & Gynecology $48.69

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Rabavert

These are the largest totals companies reported as associated with Rabavert. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Alicia Peacock	Lakewood, CO	Family	$308.06
Anne Murphy	Colorado Springs, CO	Family	$146.28
Raul Castellanos	Rio Piedras, PR	General Practice	$48.69
Eugenio Barbosa Del Valle	San Juan, PR	General Practice	$48.69
Basilisa Rivera	Caguas, PR		$48.69
Melissa Wheeler	Caguas, PR	Family Medicine	$48.69
Jossan Gomez-Consuegra	Guaynabo, PR	Medical	$48.69
Marta Irizarry-Egipciaco	San Juan, PR	Medical	$48.69
Edna Ortiz-Sanabria	Guaynabo, PR	Pediatrics	$48.69
Carlos Baez- Marin	Manati, PR	Obstetrics & Gynecology	$48.69

Prescribed Rabavert?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.